Joint inflammation is one of the most prevalent conditions in the primary care setting. It is also one of the most common health concerns among the elderly, as well as among younger physically active people.
Addressing joint discomfort before it progresses and becomes more problematic will go a long way in helping to support active, independent lifestyles, and by extension, overall health and well-being.
In this session, Vaughn DuBow and Vijaya Juturu, PhD, of Lonza Consumer Health & Nutrition, will present the latest clinical research on joint health ingredients, with a particular focus on undenatured type II collagen. UC-II, as it is known, activates T-reg cells in the gut wall, which in turn release a cascade of anti-inflammatory cytokines (IL-10 and TGF-β). Several human studies have shown that supplementation with UC-II can improve joint function and reduce WOMAC scores, in both healthy active young adults, and in older osteoarthritic subjects.
DuBow and Juturu also share product dosage and delivery forms that improve patient compliance with joint health supplementation regimens.
Sponsored by Lonza Consumer Health & Nutrition
Vaughn DuBow is the North American Marketing Manager at Lonza for their Hard Capsule, Ingredient, and Dosage Form Solutions portfolios. He has over 12 years of experience in the pharmaceutical, dietary supplement, and fitness industries.
Vijaya Juturu, PhD, is Senior Manager of Research & Development, Consumer Health & Nutrition at Lonza Inc, in Morristown, NJ. She is involved in basic, clinical, and innovation research as well as regulatory submissions of nutritional supplements.